Brain stimulation: which startup is ahead?

Brain stimulation: which startup is actually ahead?

Which brain stimulation startups are we actually comparing?

The credible brain stimulation startup field currently contains ten companies, once we separate regulated therapies from wellness headsets, recording-first brain-computer interfaces and established medical-device manufacturers.

We include private companies whose main product deliberately changes brain activity to treat a neurological or psychiatric condition. That covers electrical stimulation, magnetic stimulation, sensory entrainment and implanted adaptive systems. The technology can be external or implanted, but it must be moving toward genuine clinical use.

That definition excludes Neuralink, Synchron and Precision Neuroscience. Their main products currently record neural activity so patients can communicate with or control external devices. Stimulation may eventually become part of those platforms, but it is not their main commercial purpose today.

We also exclude public or long-established manufacturers such as Medtronic, Neuronetics, BrainsWay, NeuroPace and NeuroSigma. They still shape the market and could overpower smaller entrants, but including them in a startup ranking would make the comparison incoherent. Consumer products such as Mave Health also sit outside the final ranking because their focus and stress claims are not equivalent to an approved medical indication.

Funding totals are less tidy than product approvals or trial results. Private companies sometimes announce equity, grants and venture debt together, while databases may miss older rounds. The figures below represent the best publicly traceable totals rather than falsely precise accounting.

Startup	Main brain stimulation product	Publicly traceable funding	Why the company belongs
Flow Neuroscience	At-home tDCS for major depressive disorder	About $12M	FDA-approved home treatment with more than 55,000 reported users
Magnus Medical	Personalized, accelerated TMS for treatment-resistant depression	At least $50M publicly disclosed	Cleared treatment with growing provider and insurance coverage
Neurolief	At-home multichannel brain stimulation for depression	About $11M-$17M	Recently approved by the FDA after a randomized pivotal study
Sooma	Clinician-supervised and at-home tDCS for depression	About €7.5M	More than 30,000 patients treated across a large international clinic network
Cognito Therapeutics	Synchronized light-and-sound stimulation for Alzheimer's disease	About $233M	Running the category's largest late-stage Alzheimer's program
Newronika	Adaptive deep brain stimulation for Parkinson's disease	About €22M	Commercially authorized closed-loop DBS system in Europe
INBRAIN Neuroelectronics	Graphene neural interfaces that record and stimulate	More than $100M	Human-tested graphene platform aimed at high-resolution brain therapy
Neuroelectrics	EEG-guided multichannel electrical stimulation	About $18M	Mature research platform with therapeutic epilepsy and depression programs
Motif Neurotech	Wireless, minimally invasive implant for severe depression	$18.75M equity plus £5.8M in grants	Authorized to begin its first U.S. therapeutic implant study
Inner Cosmos	Implanted stimulation system for refractory depression	About $12M	One of the few psychiatric implant startups with initial human use

Is there a clear brain stimulation startup leader today?

Flow Neuroscience leads the brain stimulation startup market today, although Magnus Medical is close enough to make the race genuinely competitive.

Flow has assembled the broadest combination of regulatory approval, real patient use and a treatment model that can travel through the mail rather than through a specialist hospital. Its reported user base is already measured in tens of thousands. The company still has work to do in the United States, where broader commercial availability is planned for later this year, but the underlying product is no longer experimental.

Magnus occupies a different position. Its personalized SAINT treatment produces the strongest published short-term depression results in this group, and the company now operates through providers across 14 U.S. states. More than 80 million insured lives reportedly have some form of access, while CMS created a payment route worth roughly $19,700 for the complete hospital-outpatient protocol. That gives Magnus a stronger American medical-business engine than Flow currently has.

Flow leads accessible home treatment for depression. Sooma is its closest international rival in clinician-supervised tDCS, while Neurolief has become the strongest new U.S. entrant for patients who have already failed medication.

Magnus leads accelerated, personalized treatment for severe depression. The product requires more infrastructure and costs far more, but its published short-term outcomes are unmatched in this comparison. Magnus and Flow may therefore serve overlapping patients without competing for every prescription.

Cognito stands alone in late-stage non-invasive stimulation for Alzheimer's disease. Its HOPE trial enrolled roughly 670 participants, far larger than the programs run by most other startups here. A positive result would create a new therapeutic segment rather than simply take share from depression-device companies.

Newronika leads startup-built adaptive DBS in commercial readiness. INBRAIN leads in graphene-based high-resolution interfaces. Motif has the most compelling minimally invasive wireless implant concept for depression, while Inner Cosmos has already generated limited long-term human experience.

The distance is narrow at the top and much wider after it. Flow leads the broadest commercially relevant segment, Magnus is the only immediate challenger, and the rest of the field remains split among narrower specialties.

If you want more recent data on this point, please see our latest neurotechnology market report.

Which brain stimulation startup has the strongest regulatory position?

Flow Neuroscience and Neurolief currently share the strongest formal regulatory position, while Magnus Medical has built the strongest reimbursed specialist pathway.

Flow's FL-100 received FDA premarket approval for adults with moderate-to-severe major depressive disorder who are not considered treatment-resistant. Doctors can prescribe it by itself or alongside another treatment, and patients complete the sessions at home. The FDA used the PMA pathway, which involves a direct review of safety and effectiveness rather than relying mainly on similarity to an older device.

Neurolief has now reached the same broad regulatory level. The FDA approved Proliv Rx as an adjunctive treatment for adults with depression who had failed at least one antidepressant medication. Patients can use it at home or in a clinic. This recent approval changes the competitive picture because Neurolief had previously looked like another promising clinical-stage company; it now owns one of only a few approved home-based brain stimulation treatments for depression.

Magnus took the 510(k) route for SAINT, its MRI-guided accelerated TMS protocol. The product treats patients whose depression has not improved sufficiently after antidepressant medication. Magnus may have followed a less demanding device pathway, but it has already secured something commercially powerful: a defined reimbursement structure for a five-day treatment delivered inside specialist centers.

Sooma is approved across Europe and several other markets, while its U.S. pivotal trial remains underway. Newronika can market its adaptive DBS system in Europe but is still investigational in the United States. Cognito, INBRAIN, Neuroelectrics, Motif and Inner Cosmos cannot yet sell their lead therapeutic products as approved treatments.

Regulatory tier	Startups	What the position means today
FDA-approved therapeutic products	Flow Neuroscience, Neurolief	Approved home treatments for depression
FDA-cleared specialist treatment	Magnus Medical	Commercial U.S. treatment with established provider reimbursement
Commercial outside the U.S.	Sooma, Newronika	Real clinical availability, with major U.S. work still unfinished
Late-stage investigational	Cognito Therapeutics	Large pivotal study completed, but no therapeutic approval yet
Earlier human development	INBRAIN, Neuroelectrics, Motif, Inner Cosmos	Human research underway without broad commercial authorization

Which brain stimulation startup has the best clinical evidence?

Magnus Medical has the strongest acute efficacy result in brain stimulation, while Flow Neuroscience has the more dependable large pivotal dataset.

Magnus tested SAINT in a randomized, double-blind study involving 29 participants. Remission reached 78.6% among actively treated patients, compared with 13.3% in the sham group. Response reached 85.7%, versus 26.7% for sham. A placebo-adjusted remission gap of 65 percentage points is extraordinary in depression treatment, particularly after only five days.

The study's size is the obvious weakness: only fourteen people received active treatment. It cannot yet show how consistently other clinics will reproduce the outcome or how long remission lasts.

Flow's pivotal study offers a sturdier base. Among 173 evaluable participants, 44.9% of actively treated patients reached remission on the Hamilton Depression Rating Scale, compared with 21.8% under sham treatment. Response rates were 54.4% and 26.9%. The effect was smaller than Magnus's, but the study involved almost six times as many participants and supported a full FDA effectiveness review.

The FDA found that Flow's average symptom-score advantage was modest and that some participants may have guessed whether they received genuine stimulation. Flow's evidence is credible, but the effect is not overwhelming.

Neurolief's randomized MOOD study enrolled 124 people, with 97 included in the main modified analysis. After eight weeks, remission reached 21.3% with active treatment and 6% with sham. A broader measure of substantial clinical improvement reached 61.7%, compared with 32% under sham.

Cognito's strongest claims still rely on exploratory outcomes from an earlier 76-person Alzheimer's study. Its 670-participant HOPE trial must confirm whether the reported effects on daily functioning and brain-volume loss hold up in a properly powered pivotal test.

If you want more recent data on this point, please see our latest neurotechnology market report.

Which startup has turned brain stimulation into real commercial demand?

Flow Neuroscience has generated the most visible patient demand, while Magnus Medical currently has the strongest institutional customers and payment coverage.

Flow reports more than 55,000 users. Even allowing for the usual uncertainty around company-reported numbers, that scale places Flow well beyond clinical pilots and limited specialist launches. The product has also entered NHS-linked programs in the United Kingdom, showing that demand is coming from both individual prescriptions and organized healthcare services.

Sooma comes next on disclosed patient volume. The company says more than 30,000 people have received its treatment through over 300 clinics, hospitals and universities in more than 35 countries. This is a genuine international distribution network rather than a collection of press-release partnerships.

Magnus does not publish a cumulative patient total, which prevents a direct volume comparison. The quality of its provider base is nevertheless unusually strong. Recent company disclosures name Cleveland Clinic, UPMC, Stanford Medicine, HCA Healthcare, MUSC, UAMS and LSU Health among the institutions delivering or preparing to deliver SAINT. Magnus has also aggregated outcomes from more than 200 commercially treated patients, although that dataset remains company-reported rather than a controlled trial.

Neurolief has cleared the regulatory barrier but has not yet shown broad deployment. Its current commercial material focuses on recruiting prescribers and healthcare organizations. That is normal after a fresh approval, though it leaves a large gap between permission to sell and evidence that doctors repeatedly prescribe the treatment.

Cognito's 70 or so trial sites represent clinical-development capacity rather than customers. The same distinction applies to INBRAIN's hospital collaborations and Motif's study centers.

Which brain stimulation startup is gaining ground fastest now?

Magnus Medical is gaining ground fastest in the United States, while Sooma is posting the clearest disclosed operating growth internationally.

Magnus has recently connected several pieces that startups often struggle to assemble. More hospitals are offering SAINT, insurance access reportedly covers over 80 million lives, and CMS has created a substantial payment for the complete treatment. The company is also testing its platform in postpartum depression through a Department of Defense-supported study.

Sooma gives us cleaner growth percentages. The company reported a 40% increase in patients treated outside Finland during 2025, while sales doubled in Germany and France. It is also running a roughly 200-person U.S. pivotal trial for home treatment.

Neurolief has made the largest recent jump in competitive status. FDA approval turned Proliv Rx into a prescription product, and BrainsWay invested another $6 million after the decision. Neurolief now needs to show that physicians will prescribe it at scale.

Cognito recently raised $105 million to reach the HOPE readout, prepare an FDA submission and begin commercialization work. The financing strengthens the company, but its position still depends on the pivotal result.

Among implant startups, Newronika recently received a CE Mark for the newest release of its adaptive DBS platform. INBRAIN completed recruitment for its first human graphene-interface study, while Motif received authorization to begin therapeutic testing.

If you want more recent data on this point, please see our latest neurotechnology market report.

Which brain stimulation product is mature enough for routine care and scale?

Flow Neuroscience currently has the most routine-ready and scalable brain stimulation product, with Sooma already proving a similar model internationally.

Flow's treatment uses a headset, mobile application and remote prescription workflow. Patients complete 30-minute sessions at home, generally five times per week at the beginning and less frequently later in the course. No MRI scanner, treatment room or specialist technician is needed for every session.

Sooma has also proved that tDCS can fit ordinary clinical practice. Its devices support supervised home treatment and are used through hundreds of institutions across more than 35 countries. Its U.S. evidence package remains unfinished.

Neurolief uses a similarly scalable home model. Its pivotal trial reported 96% treatment adherence, although the company still needs to build a larger prescriber network, insurance coverage and manufacturing capacity.

Magnus is fully usable in clinical care, but the workflow is heavier. Each patient receives an individualized target based on structural and functional MRI, followed by 50 stimulation sessions over five days. Every new site needs equipment, imaging access, trained staff and tightly managed schedules.

Newronika leads the implanted group in product maturity because surgeons can already use its adaptive DBS system in Europe. INBRAIN, Motif and Inner Cosmos remain in small human studies.

Which brain stimulation startup offers the best economics?

Flow Neuroscience offers the lowest-friction economics for patients, while Magnus Medical offers the strongest revenue model for specialist providers.

Flow's treatment can be delivered with a relatively inexpensive headset and remote clinical oversight. Public reporting has suggested a U.S. device price around $500, although final insurance coverage and patient costs may vary as commercial distribution expands. The larger saving comes from avoiding dozens of clinic visits, MRI targeting and repeated use of expensive treatment equipment.

Magnus sits at the other end of the market. CMS's national-average payment is approximately $19,703 for the complete five-day protocol, including individualized targeting. That makes SAINT far more expensive than home stimulation, but it also gives hospitals enough revenue to justify staff, equipment and treatment capacity. For severely ill patients who have already failed medication, a rapid intervention can still be economically attractive compared with repeated hospitalization, long-term disability or months of ineffective care.

Flow is built for broad, lower-cost access. Magnus is built for intensive treatment of harder cases. A Flow prescription could eventually reach far more patients, while a Magnus patient can generate dozens of times more revenue.

Sooma should have economics close to Flow's because it uses portable equipment and supervised home sessions. Public pricing is less standardized across its many markets, which makes a clean comparison difficult. Neurolief also has an attractive home-delivery structure, although the company has not yet published enough commercial pricing and reimbursement information to judge the actual patient bill.

Cognito could offer a cheaper care setting than infused Alzheimer's drugs because Spectris is designed for home use. The burden shifts from the clinic to the household: patients and caregivers must complete roughly one hour of audiovisual treatment each day.

Product	Main economic advantage	Main economic constraint
Flow Neuroscience	Low-cost hardware and almost no treatment-center infrastructure	U.S. insurance coverage is still developing
Magnus Medical	Attractive reimbursement and high value per treated patient	Expensive equipment, imaging and specialist capacity
Sooma	Portable treatment distributed through existing clinics and homes	Prices and reimbursement vary widely by country
Neurolief	Home delivery with limited clinician time per session	Commercial pricing and coverage remain unclear
Cognito Therapeutics	Potential home alternative in a very expensive disease	Daily long-term use could create a heavy adherence burden

If you want more recent data on this point, please see our latest neurotechnology market report.

What can brain stimulation leaders do that rivals cannot easily copy?

Magnus Medical has the strongest near-term clinical workflow moat, while INBRAIN Neuroelectronics owns the most unusual hardware platform.

Magnus combines personalized functional-connectivity targeting, MRI data, neuronavigation and an accelerated schedule of 50 sessions in five days. Reproducing that system requires software, imaging expertise, trained staff, regulatory work and clinical validation.

Accelerated TMS is still a crowded research field, and established companies already own large treatment networks. Magnus must keep showing that its results can be reproduced outside Stanford.

Flow's electrical stimulation technology is easier to imitate. Its protection comes from the complete package: FDA approval, prescription software, treatment data, clinician relationships and a product that patients can operate at home.

Neurolief uses multiple electrodes to influence several neural pathways associated with depression. Its practical advantage over simpler home devices will become clearer after broader use.

INBRAIN's graphene electrodes are the boldest technical bet in the field. The company has demonstrated temporary use during brain-tumor surgery without reported device-related safety concerns, but it has not yet shown that the platform can work reliably as a permanent therapeutic implant.

Newronika can adjust DBS using recorded brain activity, although Medtronic now offers adaptive functions in its own established ecosystem. Cognito's defensibility will depend mainly on whether its pivotal Alzheimer's trial succeeds.

Which brain stimulation startup is using its funding best?

Flow Neuroscience has converted a relatively small amount of funding into the most visible patient use, whereas Cognito has raised the most money and still faces the largest clinical risk.

Flow has raised roughly $12 million according to publicly tracked financing data. Dividing that amount by its reported user base gives an extremely rough figure of about $220 in disclosed funding per user reached. That is not a customer-acquisition cost, since the money also paid for trials, product development and regulatory work. Still, it shows how much clinical reach Flow has created from a modest capital base.

Sooma also looks efficient. Approximately €7.5 million has supported treatment for more than 30,000 patients, a multinational clinic network and a U.S. pivotal program. Few medical-device startups reach that level of distribution on such limited funding.

Magnus has consumed more capital, but the output is substantial: strong trial results, FDA clearance, provider adoption and a reimbursement route. The company's efficiency cannot be calculated sensibly without revenue, utilization and cumulative treatment figures.

Neurolief has reached approval on roughly $11 million to $17 million of publicly tracked funding. That is an impressive regulatory result. Approval alone does not settle capital efficiency, because manufacturing and commercialization may require another large investment before the product generates meaningful revenue.

Cognito has raised about $233 million. The money has funded multiple studies and a 670-participant pivotal Alzheimer's trial, which is an expensive undertaking. Even so, Cognito has raised around twenty times more than Flow without an approved commercial treatment. A strong HOPE result could justify that investment quickly. A failed or marginal result would make Cognito the clearest example of capital outrunning evidence.

Motif deserves attention among the earlier implant companies. It has reached an authorized therapeutic human study with $18.75 million in equity funding and substantial non-dilutive grants.

How much can we trust the brain stimulation startup data?

The brain stimulation ranking is reliable at the top and considerably less reliable below fifth place.

Flow, Magnus and Neurolief have FDA documents that expose trial design, outcomes, adverse events and regulatory reasoning. Peer-reviewed studies provide further scrutiny.

Sooma's patient and growth figures come mainly from the company. They are consistent enough to establish meaningful international scale, but they do not reveal completion rates, revenue per patient or clinic utilization.

Magnus has a similar commercial transparency gap. Its providers and reimbursement decisions can be verified, while cumulative patient volume, revenue and site utilization remain undisclosed.

Cognito's exploratory findings around cognition, functioning and brain volume cannot replace a successful prespecified pivotal endpoint. The HOPE result will determine how much weight those earlier findings deserve.

Evidence is much thinner among implant startups. INBRAIN has shown short-term surgical feasibility, Motif has permission to begin testing, and Inner Cosmos has reported outcomes from only a few people.

Funding totals are also approximate because databases classify grants, debt and unannounced rounds differently.

Which brain stimulation startups are actually ahead?

Flow Neuroscience is ahead overall today, Magnus Medical is the only immediate challenger, and Neurolief has moved into third place after its recent FDA approval.

Flow wins because it has cleared more of the obstacles that usually kill brain stimulation startups. It has credible randomized evidence, an approved home therapy, tens of thousands of users and a product that can scale without building a treatment center around every patient. The FDA found the average effect more modest than Flow's marketing might suggest, but no rival currently matches the complete package.

Magnus is much closer than patient totals alone suggest. SAINT has the best acute efficacy data, high-quality medical customers and unusually strong reimbursement. Magnus could overtake Flow if commercial treatment volumes expand rapidly and real-world outcomes continue to resemble the original study. For now, the intensive workflow and limited public deployment data keep it in second.

Neurolief takes third because approval changes what the company can realistically become. Proliv Rx combines home use, a difficult-to-treat patient population and a respectable randomized result. Commercial adoption remains the missing proof. A year of strong prescription growth could move Neurolief much closer to the top two.

Sooma falls just behind Neurolief despite its larger patient base. Its international business is real and growing, but the U.S. pivotal trial remains the decisive hurdle. A successful study could push Sooma back into third because the company already knows how to distribute and support treatment at scale.

Cognito ranks fifth as the high-upside outsider. No other startup has placed such a large late-stage bet on Alzheimer's disease. The company could jump several positions after a convincing pivotal result, while disappointing efficacy would leave it with the largest funding total and little commercial protection.

Newronika leads the next group through real regulatory and product maturity. INBRAIN may own more ambitious technology, but chronic therapeutic use still lies ahead. Neuroelectrics has a substantial scientific platform without equivalent therapeutic-market progress. Motif and Inner Cosmos remain early implant bets whose rankings could change quickly after a handful of meaningful clinical results.

The competitive structure is clearer than a simple funding table suggests. Flow is the current leader. Magnus is a serious challenger rather than a distant second. Neurolief and Sooma form a narrow second tier, with opposite strengths in regulation and adoption. Cognito could disrupt the entire ranking, but it must first prove that its Alzheimer's therapy works.

Rank	Startup	Why the startup holds this position
1	Flow Neuroscience	Best overall mix of approval, patient reach, home delivery and capital efficiency
2	Magnus Medical	Strongest acute results, provider economics and U.S. institutional momentum
3	Neurolief	Newly approved home treatment with solid randomized evidence; commercial rollout is still unproven
4	Sooma	Large international patient base and strong growth, but no completed U.S. pivotal pathway
5	Cognito Therapeutics	Largest clinical upside and pivotal program, with efficacy still unresolved
6	Newronika	Most commercially mature adaptive DBS startup
7	INBRAIN Neuroelectronics	Most distinctive implant hardware, several stages away from routine therapy
8	Neuroelectrics	Mature research platform with slower therapeutic commercialization
9	Motif Neurotech	Efficiently financed implant concept entering its first therapeutic human study
10	Inner Cosmos	Early human experience remains too limited to support a higher position

If you want more recent data on this point, please see our latest neurotechnology market report.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.